Method for producing L-isoleucine as well as genetically engineered bacterium and application thereof

By constructing threonine dehydrase mutants and overexpression-related enzymes that relieve feedback inhibition, the metabolic pathway is optimized, and the problems of slow growth and feedback inhibition of existing L-isoleucine-producing strains are solved, achieving high yield and high conversion rate The L-isoleucine genetically engineered strain reduces the fermentation cost and cycle.

CN118910024APending Publication Date: 2024-11-08TIANJIN UNIV OF SCI & TECH
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202410809399.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing L-isoleucine-producing strains grow slowly, have nutritional defects, and have poor genetic stability, resulting in long fermentation cycles, high costs, low yield and conversion rates, and threonine dehydrase and acetylhydroxy acid synthase are affected by L-isodisodium Leucine feedback inhibition affects accumulation efficiency.

Method used

Construct the threonine dehydrase mutant ILVAM that removes L-isoleucine feedback inhibition, and overexpresses relevant enzymes in E. coli through genetic engineering technology to establish a highly active cysthione-γ-synthesis enzyme mutant, and optimize Metabolic pathway, forming a high-yield L-isoleucine genetically engineered strain.

Benefits of technology

The high yield and high conversion rate of L-isoleucine are achieved, the fermentation cycle is shortened, the production cost is reduced, the stability of output and conversion rate is ensured, and the highest indicator reported is reached.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910024A_ABST
    Figure CN118910024A_ABST
Patent Text Reader

Abstract

The invention relates to a genetically engineered bacterium for producing L-isoleucine and application of the genetically engineered bacterium, and belongs to the field of metabolic engineering. In order to overcome the defects that wild type threonine dehydratase and acetohydroxy acid synthase are subjected to feedback inhibition of L-isoleucine, and existing L-isoleucine production strains are slow in growth, have nutritional defects, are poor in genetic stability and the like, the invention provides a threonine dehydratase mutant for relieving feedback inhibition of L-isoleucine. The L-isoleucine genetically engineered bacterium with fast growth, no nutritional deficiency and high synthesis efficiency is constructed by using the threonine dehydratase mutant, acetohydroxy acid synthase and high-activity cystathionine-gamma-synthase mutant coding genes; and the method for producing the L-isoleucine by direct fermentation of the bacterium is also used.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to a genetic engineering bacterium for producing L-isoleucine and application thereof, belonging to the field of metabolic engineering. Background technology:

[0002] L-isoleucine belongs to branched-chain amino acids and is one of the eight essential amino acids. It has a variety of physiological characteristics and is therefore widely used in many fields such as medicine, food, agriculture, and daily chemicals. At present, the main methods for producing L-isoleucine are extraction and microbial fermentation. The extraction method refers to the hydrolysis of animal and plant protein tissues with strong acid to obtain L-isoleucine. Chemical reagents such as strong acid are required during the operation, which can easily cause environmental pollution. In comparison, the microbial fermentation method has obvious advantages in industrial production due to its advantages such as simple operation, low cost, and environmental friendliness. At present, the industrial L-isoleucine production strains are all derived from mutagenesis, which have the disadvantages of slow growth, nutritional deficiencies, and poor genetic stability, resulting in long fermentation cycles, high fermentation costs, low yields and conversion rates, and unstable fermentation performance. Escherichia coli has excellent characteristics such as clear genetic background and fast growth rate, and is a commonly used chassis cell in industry.

[0003] In microbial fermentation, threonine dehydratase and acetohydroxyacid synthase are key enzymes in the biosynthetic pathway of L-isoleucine, and their activities are feedback inhibited by L-isoleucine. Therefore, relieving the feedback inhibition of threonine dehydratase and acetohydroxyacid synthase by the corresponding metabolites in the cell is necessary for the accumulation of L-isoleucine.

[0004] In summary, using Escherichia coli as the chassis cell, it is expected to achieve excessive accumulation of L-isoleucine by eliminating feedback inhibition of key enzymes and strengthening metabolic pathways. Summary of the invention:

[0005] In order to overcome the feedback inhibition of wild-type threonine dehydratase and acetohydroxyacid synthase by L-isoleucine and the shortcomings of existing L-isoleucine production strains such as slow growth, nutritional deficiency and poor genetic stability, the present invention provides a threonine dehydratase mutant that relieves the feedback inhibition of L-isoleucine, and utilizes the encoding genes of the threonine dehydratase mutant, acetohydroxyacid synthase and highly active cystathionine-γ-synthase mutant to construct an L-isoleucine genetic engineering bacterium with fast growth, no nutritional deficiency and high synthesis efficiency, and a method for directly fermenting and producing L-isoleucine by using the bacterium.

[0006] The technical solution adopted by the present invention to solve the above technical problems is as follows:

[0007] One of the technical solutions provided by the present invention is: a threonine dehydratase mutant that relieves L-isoleucine feedback inhibition, specifically ILVA with an amino acid sequence as shown in SEQ ID NO.1 MThe encoding gene of the threonine dehydratase mutant is ilvA M The nucleotide sequence is shown in the sequence listing SEQ ID NO.2.

[0008] The threonine dehydratase mutant is derived from a mutant strain of Corynebacterium glutamicum, and the mutant screening process is as follows: Corynebacterium glutamicum ATCC13032 is used as a starting strain, and the strain ILE396 is screened out on a basic culture medium containing 50 mg / L alpha-aminobutyric acid through plasma mutagenesis at normal pressure and room temperature; and ILE396 is used as a starting strain, and the strain ILE693 is screened out on a basic culture medium containing 50 mg / L thioisoleucine through plasma mutagenesis at normal pressure and room temperature.

[0009] The ILE693 genome was extracted, and the threonine dehydratase encoding gene was amplified by PCR using designed primers. The PCR product was recovered and sequenced, and it was found that the threonine dehydratase encoded by the gene had the following amino acid mutations relative to the wild-type threonine dehydratase from Corynebacterium glutamicum ATCC13032: V140M, P363L.

[0010] The enzyme activity of the wild-type threonine dehydratase ILVA decreases significantly with the increase of L-isoleucine concentration, and is almost inactive when the L-isoleucine concentration is higher than 10 mmol / L. M When the concentration of L-isoleucine was 0-50mmol / L, ILVA M There was no significant decrease in enzyme activity, which means that the mutant relieved the feedback inhibition of L-isoleucine. M The advantage of is that it is still active in the presence of L-isoleucine to ensure the synthesis of a large amount of L-isoleucine.

[0011] The second technical solution provided by the present invention is the threonine dehydratase mutant ILVA described in the first technical solution M The invention relates to an application of the invention, in particular to an application in relieving the feedback inhibition of L-isoleucine, and more particularly to an application in producing L-isoleucine.

[0012] The third technical solution provided by the present invention is a method for producing L-isoleucine, wherein the method uses Escherichia coli as a starting strain, knocks out the lactose operon repressor protein encoding gene lacI on the genome, and overexpresses the threonine dehydratase encoding gene ilvA that releases feedback inhibition as described in the first technical solution on the genome. M, overexpression of the ilvBN gene encoding the acetohydroxyacid synthase that relieves feedback inhibition in the genome M , overexpressing aspartate kinase / homoserine dehydrogenase encoding gene thrA, homoserine kinase encoding gene thrB and threonine synthetase encoding gene thrC in the genome, overexpressing aspartate aminotransferase encoding gene aspA in the genome, overexpressing Bacillus subtilis leucine dehydrogenase encoding gene bcd in the genome, knocking out branched chain amino acid aminotransferase encoding gene ilvE, overexpressing pyridine nucleotide transhydrogenase encoding gene pntAB in the genome, knocking out isocitrate lyase encoding gene aceA, knocking out succinyl-CoA synthetase encoding gene sucCD, replacing the start codon ATG of serine acetyltransferase encoding gene cysE with GTG in the genome, overexpressing homoserine-O-acyltransferase encoding gene metA and cystathionine-γ-synthase mutant encoding gene metB M This is achieved by overexpressing the L-isoleucine export protein encoding gene ygaZH or brnFE in the genome and knocking out the L-isoleucine import protein encoding gene brnQ.

[0013] Furthermore, the starting strain of Escherichia coli is Escherichia coli W3110;

[0014] Furthermore, a plasmid was used to overexpress the homoserine-O-acyltransferase encoding gene metA and the cystathionine-γ-synthase mutant encoding gene metB. M ;

[0015] Furthermore, the lactose operon repressor protein encoding gene lacI is from Escherichia coli W3110, Protein ID in NCBI: BAE76127.1;

[0016] Furthermore, the threonine dehydratase encoding gene ilvA that releases feedback inhibition M Derived from Corynebacterium glutamicum ILE693, the nucleotide sequence is shown in SEQ ID NO.2;

[0017] Furthermore, the acetohydroxyacid synthase encoding gene ilvBN that releases feedback inhibition M Derived from Corynebacterium glutamicum ILE693, the nucleotide sequence is shown in SEQ ID NO.3;

[0018] Furthermore, the aspartate kinase / homoserine dehydrogenase encoding gene thrA, homoserine kinase encoding gene thrB and threonine synthetase encoding gene thrC are from Escherichia coli W3110, with Protein IDs in NCBI: BAB96579.2, BAB96580.2 and BAB96581.1;

[0019] Furthermore, the aspartate aminotransferase encoding gene aspA is from Escherichia coli W3110, Protein ID in NCBI: BAE78141.1;

[0020] Furthermore, the leucine dehydrogenase encoding gene bcd is from Bacillus subtilis 168, Protein ID in NCBI: NP_390288.1;

[0021] Furthermore, the branched chain amino acid aminotransferase encoding gene ilvE is from Escherichia coli W3110, NCBI Protein ID: BAE77527.1;

[0022] Furthermore, the pyridine nucleotide transhydrogenase encoding gene pntAB is from Escherichia coli W3110, Protein ID in NCBI: BAA15342.1-BAA15336.1;

[0023] Furthermore, the isocitrate lyase encoding gene aceA is from Escherichia coli W3110, Protein ID in NCBI: BAE78017.1;

[0024] Furthermore, the succinyl-CoA synthetase encoding gene sucCD is from Escherichia coli W3110, Protein ID in NCBI: BAA35394.1-BAA35395.1;

[0025] Furthermore, the serine acetyltransferase encoding gene cysE is from Escherichia coli W3110, Protein ID in NCBI: BAE77685.1;

[0026] Furthermore, the homoserine-O-acyltransferase encoding gene metA is from Escherichia coli W3110, Protein ID in NCBI: BAE78015.1;

[0027] Furthermore, the cystathionine-γ-synthase mutant encoding gene metB M , the nucleotide sequence is shown in SEQ ID NO.4;

[0028] Furthermore, the L-isoleucine export protein encoding gene ygaZH is from Escherichia coli W3110, Protein ID in NCBI: BAE76784.1-BAA16545.1;

[0029] Furthermore, the L-isoleucine export protein encoding gene brnFE is from Corynebacterium glutamicum 13032, Protein ID in NCBI: CAF18829.1-CAF18830.1;

[0030] Furthermore, the L-isoleucine import protein encoding gene brnQ is from Escherichia coli W3110, Protein ID in NCBI: BAE76181.1;

[0031] Furthermore, the homoserine-O-acyltransferase encoding gene metA and the cystathionine-γ-synthase mutant encoding gene metB M The plasmid vector used for overexpression was pUC19.

[0032] The fourth technical solution provided by the present invention is a strain for producing L-isoleucine, wherein the strain is based on Escherichia coli W3110 as a starting strain, the lactose operon repressor protein encoding gene lacI is knocked out on the genome, and the threonine dehydratase encoding gene ilvA that releases feedback inhibition is overexpressed on the genome M , overexpression of the ilvBN gene encoding the acetohydroxyacid synthase that relieves feedback inhibition in the genome M , overexpressed aspartate kinase / homoserine dehydrogenase encoding gene thrA, homoserine kinase encoding gene thrB and threonine synthetase encoding gene thrC in the genome, overexpressed aspartate aminotransferase encoding gene aspA in the genome, overexpressed Bacillus subtilis leucine dehydrogenase encoding gene bcd in the genome, knocked out branched chain amino acid aminotransferase encoding gene ilvE, overexpressed pyridine nucleotide transhydrogenase encoding gene pntAB in the genome, knocked out isocitrate lyase encoding gene aceA, knocked out succinyl-CoA synthetase encoding gene sucCD, replaced the start codon ATG of serine acetyltransferase encoding gene cysE with GTG in the genome, overexpressed homoserine-O-acyltransferase encoding gene metA and cystathionine-γ-synthase mutant encoding gene metB using plasmid M , the L-isoleucine export protein encoding gene brnFE was overexpressed in the genome, and the L-isoleucine import protein encoding gene brnQ was knocked out, and finally a L-isoleucine high-producing strain was obtained.

[0033] The fifth technical solution provided by the present invention is the use of the strain described in the fourth technical solution in the production of L-isoleucine; in particular, the use in the fermentation production of L-isoleucine, and the specific method is as follows:

[0034] The seed culture was inoculated into the fermentation medium at a rate of 5-10% for fermentation. During the 0-12h of fermentation, the ventilation rate was 2-4m 3 / h, stirring speed 400-900rpm, tank pressure 0.1-0.15MPa to maintain dissolved oxygen at 40-50%, pH at 7.0-7.5, culture temperature 37°C; adjust the fermentation temperature and dissolved oxygen level from 12th to 48th hour of fermentation, and adjust the ventilation volume to 3-5m 3 / h, stirring speed to 500-900rpm, tank pressure 0.05-0.1MPa to maintain dissolved oxygen level at 30-40%, pH 7.0-7.5 by adding ammonia water, culture temperature 35°C; the whole fermentation period 0-48h, the residual sugar concentration is maintained at 0.1-0.5% (W / V) during the fermentation process;

[0035] At the end of fermentation, the L-isoleucine concentration in the fermentation broth reached 45.3-61.9 g / L.

[0036] Beneficial effects:

[0037] (1) The present invention uses E. coli W3110 as the starting strain, uses system metabolic engineering to enhance the L-isoleucine synthesis flux, increase the precursor supply, improve the redox flux, build a metabolic pathway that couples cell growth and L-isoleucine synthesis, and modify the transport system, and finally constructs a strain with high L-isoleucine production. Batch fed fermentation was carried out in a 5L fermenter, and the L-isoleucine production reached 61.9g / L at 40h, and the conversion rate and fermentation intensity were 31.9% and 1.54g / L / h, respectively.

[0038] (2) The fermentation process adopted by the present invention is simple, easy to control, and has low production cost, which is conducive to the promotion and application of industrial production. Compared with the prior art, the engineered strain and its fermentation process obtained by the present invention have no nutritional defects, a short fermentation cycle, and high L-isoleucine production and conversion rate, which are the highest indicators reported so far. Description of the drawings:

[0039] Figure 1 The effect of L-isoleucine on ILVA and ILVA in Example 1 M The impact of activity;

[0040] Figure 2 This is the fermentation process curve of the L-isoleucine genetically engineered bacteria ISO-11 in a 5L fermenter in Example 17. Specific implementation method:

[0041] In order to make the purpose, technical solution and advantages of this patent more clear, this patent is further described in detail in combination with specific embodiments. It should be understood that the specific embodiments described here are only used to explain this patent and are not used to limit the present invention.

[0042] The substance detection method in the fermentation process of the present invention is as follows:

[0043] (1) L-isoleucine detection method

[0044] L-isoleucine was quantitatively analyzed using a high-performance liquid chromatography (HPLC) system. The sample was derivatized with 2,4-dinitrofluorobenzene so that it could be detected by a liquid phase signal analyzer. The specific process is as follows:

[0045] Sample derivatization method: Take 1 ml of fermentation broth and centrifuge it at 13000×g for 3 minutes, then take the supernatant and dilute it 10 times with deionized water, and use 0.8% (V / V) 2,4-dinitrofluorobenzene to derivatize the fermentation broth (the above supernatant is passed through a 0.22μm organic membrane for standby use, add 200μL of derivatization buffer, 10μL of the supernatant after passing through the membrane and 300μL of the derivatization agent to a 1.5mL EP tube and shake evenly, place it in a 65℃ water bath in a dark water bath for 60min, then take it out and cool it, take 690μL of the constant volume buffer to make it to 1.2mL, mix and pass it through the membrane), filter it into the sample pool, use 50% acetonitrile and 4.1g / L sodium acetate after ultrasonic filtration as the organic phase and inorganic phase respectively, adjust the column temperature to 33℃, and when the baseline is 0 and the pressure line is horizontal, start the determination of the sample to be tested. The detection conditions are as follows: Agilent AAA (4.6 mm×150 mm, 5-Micron), acetonitrile / sodium acetate binary gradient elution, flow rate 1 mL / min, column temperature 33° C., and detection wavelength 360 nm.

[0046] (2) Detection of bacterial concentration and other products

[0047] Determine the OD of bacterial culture by spectrophotometer 600 The growth of cells was monitored. The glucose concentration during the fermentation process was detected using an SBA biosensor (SBA-40C; Biological Institute of Shandong Academy of Sciences, Jinan).

[0048] The following definitions are used in the present invention:

[0049] 1. Nomenclature of amino acid and DNA sequences

[0050] The generally accepted IUPAC nomenclature for amino acid residues is used, using the three-letter / one-letter code format. The generally accepted IUPAC nomenclature for DNA nucleic acid sequences is used.

[0051] 2. Identification of threonine dehydratase mutants

[0052] The mutated amino acid in the threonine dehydratase mutant is represented by "original amino acid + position + replaced amino acid". For example, V140M means that the amino acid at position 140 is replaced by Met from Val of the wild-type threonine dehydratase, and the position number corresponds to the amino acid sequence number of the wild-type threonine dehydratase in SEQ ID NO.5.

[0053] In the present invention, ilvA represents a wild-type threonine dehydratase encoding gene (shown in SEQ ID NO.6), ILVA represents a wild-type threonine dehydratase (shown in SEQ ID NO.5); ilvA M is a threonine dehydratase mutant gene (shown in SEQ ID NO.2); ILVA M It is a threonine dehydratase mutant (shown in SEQ ID NO.1). The amino acid comparison before and after mutation is shown in the following table:

[0054]

[0055]

[0056] The primer sequences used in the embodiments of the present invention are shown in the following table:

[0057]

[0058]

[0059]

[0060] The strain genotypes in the present invention are shown in the following table

[0061]

[0062] It should be particularly noted that during the construction of the strain of the present invention, the editing order of the genes can be adjusted according to actual needs, and the order of editing will not affect the effect of the strain finally obtained in producing L-isoleucine.

[0063] The present invention is further explained below by means of specific examples.

[0064] Example 1: Threonine dehydratase encoding gene ilvA that relieves L-isoleucine feedback inhibition M (1) Screening of mutant strains resistant to L-isoleucine structural analogs

[0065] ① Preparation of Corynebacterium glutamicum ATCC13032 bacterial suspension

[0066] Corynebacterium glutamicum ATCC13032 was inoculated into LB liquid medium and cultured at 32°C, 200 rpm for 12 h. The cells were collected by centrifugation, washed three times with sterile saline and resuspended to a concentration of OD 600 =0.6-0.8, take 10μL of bacterial suspension and apply it on the slide.

[0067] ② Atmospheric pressure and room temperature plasma mutagenesis

[0068] The mutagenesis parameters were: the slide was placed 2 mm from the airflow port, the power was 120 W, the airflow was 10 SLM, and the action time was 25 s. ③ Screening of mutant strains resistant to α-aminobutyric acid, a structural analog of L-isoleucine

[0069] The bacterial suspension induced in step ② was spread on a basic culture medium containing 50 mg / L α-aminobutyric acid, and cultured at 35°C for 48 hours, and then the strain with the largest colony was selected.

[0070] ④ Determination of the ability of strains to produce L-isoleucine

[0071] The strain screened in step ③ was cultured in a 96-well plate using a seed culture medium, and then inoculated into a 96-well plate containing a fermentation culture medium at an inoculation rate of 10% for a fermentation experiment. ILE396 had the highest L-isoleucine production.

[0072] ⑤ Screening of mutant strains resistant to the structural analogue of L-isoleucine, thioisoleucine, and determination of their ability to produce L-isoleucine

[0073] ILE396 was used as the mutagenesis target, and steps ① and ② were repeated. The mutagenesis bacterial suspension was spread on a basic medium containing 50 mg / L thioisoleucine, and cultured at 35°C for 48 hours. The strain with the largest colony was selected. Step ④ was repeated, and ILE693 had the highest L-isoleucine production.

[0074] ⑥ Culture medium

[0075] Seed culture medium: glucose 25 g / L, yeast powder 5 g / L, (NH4)2SO4 5 g / L, KH2PO4 2 g / L, MnSO4 0.6 g / L, corn steep liquor 40 mL, pH 7.0-7.5, high pressure steam sterilization at 115 °C for 15 min.

[0076] Fermentation medium: glucose 80g / L, (NH4)2SO4 3g / L, KH2PO4 1.5g / L, MgSO4·7H2O 0.6g / L, MnSO4 0.015g / L, V B1 0.001g / L, 30mL corn steep liquor, pH 7.0-7.5, 115℃ high pressure steam sterilization for 15min.

[0077] ⑦Detection method

[0078] The fermentation broth was centrifuged at 8000 g for 5 min, and the supernatant was taken out. It was derivatized with 0.8% (V / V) 2,4-dinitrofluorobenzene, and the L-isoleucine content was determined by high performance liquid chromatography. The detection conditions were: Agilent AAA (4.6 mm×150 mm, 5-Micron), acetonitrile / sodium acetate binary gradient elution, column temperature of 33° C., detection wavelength of 360 nm. The L-isoleucine yield was determined based on the measurement results of the high performance liquid chromatography method and the comparison of the peak time and peak area with those of the standard.

[0079] (2) Release of L-isoleucine feedback inhibition of the threonine dehydratase encoding gene ilvA M Acquisition of mutants

[0080] The ILE693 genome was extracted and PCR amplified using primers ilvA-1 and ilvA-2. The PCR conditions were: 94°C for 5 min for 1 cycle, 94°C for 30 s, 56°C for 30 s, 72°C for 1 min for 30 cycles, and 72°C for 10 min for 1 cycle. The reaction system was 100 μL. 10 μL of PCR product was detected by 1.5% agarose gel electrophoresis. The target fragment amplified by PCR was recovered and ligated to pMD TM 18-T Vector and transformed into E. coli DH5α competent cells, then spread on LB solid medium containing ampicillin (100 μg / mL) and cultured upside down at 37°C for 24 hours. Pick 3 single clones, extract the recombinant plasmid and determine its sequence.

[0081] The sequencing results showed that compared with the wild-type ilvA, the threonine dehydratase encoded by the mutant gene had V140M and P363L mutations, and the mutant was named ILVA M , the encoding gene was named ilvA M .

[0082] (3) Threonine dehydratase mutant ILVA M Comparison of enzymatic properties with wild-type threonine dehydratase ILVA

[0083] The genomes of Corynebacterium glutamicum ATCC13032 and ILE693 were used as templates, and PCR amplification was performed using primers IA-1 and IA-2, respectively. The products were recovered and ligated to the pET-His plasmid digested with BamH I, and then transformed into Escherichia coli BL21 (DE3) to obtain strains E. coli-ilvA and E. coli-ilvA MIPTG was used to isolate E.coli-ilvA and E.coli-ilvA M Inducible expression of recombinant proteins ILVA and ILVA M , collect the bacteria, resuspend them in 100 mmol / L potassium phosphate buffer (pH 8.0), perform ultrasonic disruption and centrifugation, and take the supernatant.

[0084] ILVA M The enzyme activity determination method of ILVA is as follows: 100 μL of the above supernatant was added to 1 mL of potassium phosphate buffer (100 mmol / L, pH 8.0 containing 40 mmol / L L-threonine and 1 mmol / L pyridoxal phosphate), reacted at 22°C for 15 min, and 1 mL of stop solution (0.9% sodium acetate) was added to terminate the enzymatic reaction. 1 mL of the reaction solution was taken to determine the concentration of 2-ketobutyric acid. The content of 2-ketobutyric acid was determined using an UltiMate 3000 (Thermo Scientific) high performance liquid chromatograph. The detection conditions were: chromatographic column REzex RoA-organic Acid H + , mobile phase 5mmol / L H2SO4, flow rate 0.5mL / min, column temperature 30℃, detection wavelength 215nm, injection volume 20μL. ILVA M The activities of ILVA and ILVA were 15.5 and 15.7 nmol / (min·mg total protein), respectively, with no significant difference between the two.

[0085] L-Isoleucine for ILVA M The method for determining the effect of ILVA on the enzyme activity was as follows: 0, 10, 20, 30, 40, and 50 mmol / L L-isoleucine were added to the above reaction solution, and then the amount of 2-ketobutyric acid produced was calculated to investigate the effect of ILVA on the enzyme activity. M Eliminate the feedback inhibition of L-isoleucine. The results show that ( Figure 1 ), the enzyme activity of ILVA decreased rapidly with the increase of L-isoleucine concentration, and was almost inactive when the L-isoleucine concentration was higher than 10mmol / L, indicating that the enzyme was feedback inhibited by L-isoleucine; while the mutant ILVA M The enzyme activity of ILVA did not decrease significantly with the increase of L-isoleucine concentration (0-50mmol / L), indicating that the mutant ILVA M The feedback inhibition of L-isoleucine is relieved.

[0086] Based on the above results, the threonine dehydratase mutant ILVA M The feedback inhibition of L-isoleucine was relieved, and its activity was not significantly reduced at a concentration of 50mmoL L-isoleucine compared with that without L-isoleucine.M The amino acid sequence and nucleotide sequence are as follows:

[0087] Threonine dehydratase mutant ILVA M , SEQ ID NO.1:

[0088] MSETYVSEKSPGVMASGAELIRAADIQTAQARISSVIAPTPLQYCPRLSEETGAEIYLKREDLQDVRSYKIRGALNSGAQLTQEQRDAGIVAASAGNHAQGVAYVCKSL GVQGRIYVPVQTPKQKRDRIMVHGGEFVSLMVTGNNFDEASAAAHEDAERTGATLIEPFDARNTVIGQGTVAAEILSQLTSMGKSADHVMVPVGGGGLLAGVVSYMADM APRTAIVGIEPAGAASMQAALHNGGPITLETVDPFVDGAAVKRVGDLNYTIVEKNQGRVHMMSATEGAVCTEMLDLYQNEGIIAEPAGALSIAGLKEMSFAPGSVVVCI ISGGNNDVLRYAEIAERSLVHRGLKHYFLVNFPQKLGQLRHFLEDILGPDDITLFEYLKRNNRETGTALVGIHLSEASGLDSLLERMEESAIDSRRLEPGTPEYEYLT.

[0089] Threonine dehydratase mutant encoding gene ilvA M , SEQ ID NO.2:

[0090]

[0091] Example 2: Construction of lacI knockout strain E. coli W3110ΔlacI

[0092] (1) Overlapping fragment U lacI -D lacI Construction

[0093] Using the E. coli W3110 genome as a template, primers lacI-1 / lacI-2 and lacI-3 / lacI-4 were used to amplify the upstream and downstream homology arms of lacI, and then overlapping PCR was used to obtain a fusion fragment U containing the upstream and downstream homology arms of lacI. lacI -D lacI (2) Construction of pGRB-lacI plasmid

[0094] According to the lacI sequence, the gRNA 20bp forward and reverse sequences pGRB-lacI-S / pGRB-lacI-A were designed and synthesized. After annealing, the two were connected to the plasmid pGRB using the recombination kit ClonExpress IIOne Step Cloning Kit (Nanjing Novogene Medical Technology Co., Ltd.). The recombinant plasmid pGRB-lacI was obtained by transformation of E. coli DH5α, screening with LB solid culture medium containing 100 μg / mL ampicillin, and sequencing identification.

[0095] (3) Construction of lacI knockout strain E. coli W3110ΔlacI

[0096] The recombinant plasmid pGRB-lacI and fusion fragment U lacI -D lacI Transformed into E.coliW3110 competent cells containing pREDcas9 plasmid, spread on LB solid culture containing 100μg / mL spectinomycin and ampicillin after recovery, and cultured at 32℃ overnight. The next day, colony PCR was performed with primers lacI-1 / lacI-4 to screen positive transformants. Activated transformants, added arabinose with a final concentration of 0.2mmol / L, cultured at 32℃ overnight to lose pGRB-lacI; then cultured at 42℃ overnight to lose pREDcas9 plasmid, and obtained strain E.coli W3110ΔlacI.

[0097] Example 3: Construction of L-isoleucine engineering strain ISO-1

[0098] (1) Overlapping fragment U yjiP -P trc -ilvA M -T trc -DyjiP Construction

[0099] Using the E. coli W3110 genome as a template, the upstream and downstream homology arms of yjiP were amplified using primers U-yjiP-S / U-yjiP-A and D-yjiP-S / D-yjiP-A, respectively. Using the C. glutamicum ILE693 genome as a template, the ilvA M -S and ilvA M -A amplification contains P trc Promoter (TTGACAATTAATCATCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGACC), T trc Terminator (CAAATAAAACGAAAGGCTCAGTCGAAAGACTGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAAT) and ilvA M The fragment P of the gene (shown in SEQ ID NO.2) trc -ilvA M -T trc (P trc Promoter and T trc The terminator has been designed in the primer ilvA M -S and ilvA M -A, P trc -ilvA M -T trc After the PCR product was recovered, the primers U-yjiP-S / D-yjiP-A were used to obtain the fragment containing the upstream and downstream homology arms of yjiP, P trc -ilvA M -T trc Fusion fragment U yjiP -P trc -ilvA M -T trc -D yjiP .

[0100] (2) Construction of pGRB-yjiP plasmid

[0101] According to the yjiP sequence, the gRNA 20bp forward and reverse sequences pGRB-yjiP-S and pGRB-yjiP-A were designed and synthesized, and the recombinant plasmid pGRB-yjiP was constructed using the same method as step (2) of Example 2.

[0102] (3) Construction of L-isoleucine engineered strain ISO-1

[0103] The recombinant plasmid pGRB-yjiP and fusion fragment U yjiP -P trc -ilvA M -T trc -D yjiP The strain was transformed into competent cells of E. coli W3110ΔlacI containing the pREDcas9 plasmid, and positive transformants were identified using primers U-yjiP-S / D-yjiP-A. The plasmid was lost in the same manner as step (3) of Example 2 to obtain strain ISO-1.

[0104] Example 4: Construction of L-isoleucine engineering strain ISO-2

[0105] (1) Overlapping fragment U yncI -P trc -ilvBN M -T trc -D yncI Construction

[0106] Using E. coli W3110 as a template, primers U-yncI-S / U-yncI-A and D-yncI-S / D-yncI-A were used to amplify the upstream and downstream homology arms of yncI, respectively; the ilvBN shown in SEQ ID NO.3 was synthesized by gene M The gene fragment was used as a template and primer ilvBN was used M -S and ilvBN M -A amplification contains P trc Promoter, T trc Terminator and ilvBN M P trc -ilvBN M -T trc (P trc Promoter and T trc The terminator has been designed in the primer ilvBN M -S and ilvBN M -A). After the PCR product was recovered, primers U-yncI-S / D-yncI-A were used to obtain overlapping PCR containing the upstream and downstream homology arms of yncI, P trc -ilvBN M -T trc Fusion fragment U yncI -P trc -ilvBN M -T trc -D yncI .

[0107] (2) Construction of pGRB-yncI plasmid

[0108] According to the yncI sequence, the gRNA 20bp forward and reverse sequences pGRB-yncI-S and pGRB-yncI-A were designed and synthesized, and the recombinant plasmid pGRB-yncI was constructed using the same method as step (2) of Example 2.

[0109] (3) Construction of L-isoleucine engineered strain ISO-2

[0110] The recombinant plasmid pGRB-yncI and fusion fragment U yncI -P trc -ilvBN M -T trc -D yncI The strain was transformed into competent cells of ISO-1 containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-yncI-S / D-yncI-A. The plasmid was lost in the same manner as step (3) of Example 2 to obtain strain ISO-2.

[0111] Example 5: Construction of L-isoleucine engineering strain ISO-3

[0112] (1) Overlapping fragment U ylbE -P trc -thrABC-T trc -D ylbE Construction

[0113] Using the E. coli W3110 genome as a template, primers U-ylbE-S / U-ylbE-A, D-ylbE-S / D-ylbE-A, and thrABC-S / thrABC-A were used to amplify the upstream and downstream homology arms of ylbE, as well as the region containing P trc Promoter, T trc terminator and fragment P of thrABC gene trc -thrABC-T trc After the PCR products were recovered, primers U-ylbE-S / D-ylbE-A were used to obtain overlapping PCR containing the upstream and downstream homology arms of ylbE, P trc -thrABC-T trc Fusion fragment U ylbE -P trc -thrABC-T trc -D ylbE .

[0114] (2) Construction of pGRB-ylbE plasmid

[0115] According to the ylbE sequence, the gRNA 20bp forward and reverse sequences pGRB-ylbE-S and pGRB-ylbE-A were designed and synthesized, and the recombinant plasmid pGRB-ylbE was constructed using the same method as step (2) of Example 2.

[0116] (3) Construction of L-isoleucine engineered strain ISO-3

[0117] The recombinant plasmid pGRB-ylbE and fusion fragment U ylbE -P trc -thrABC-T trc -D ylbE The strain was transformed into competent cells of ISO-2 containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-ylbE-S / D-ylbE-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-3.

[0118] Example 6: Construction of L-isoleucine engineering strain ISO-4

[0119] (1) Overlapping fragment U mbhA -P trc -aspA-T trc -D mbhA Construction

[0120] Using the E. coli W3110 genome as a template, primers U-mbhA-S / U-mbhA-A, D-mbhA-S / D-mbhA-A, and aspA-S / aspA-A were used to amplify the upstream and downstream homology arms of mbhA, as well as the region containing P trc Promoter, T trc terminator and fragment P of the aspA gene trc -aspA-T trc After the PCR products were recovered, primers U-mbhA-S / D-mbhA-A were used to obtain overlapping PCR containing the upstream and downstream homology arms of mbhA, P trc -aspA-T trc Fusion fragment U mbhA -P trc -aspA-T trc -D mbhA .

[0121] (2) Construction of pGRB-mbhA plasmid

[0122] According to the mbhA sequence, the gRNA 20 bp forward and reverse sequences pGRB-mbhA-S and pGRB-mbhA-A were designed and synthesized, and the recombinant plasmid pGRB-mbhA was constructed using the same method as step (2) of Example 2.

[0123] (3) Construction of L-isoleucine engineered strain ISO-4

[0124] The recombinant plasmid pGRB-mbhA and fusion fragment U mbhA -P trc -aspA-T trc -D mbhA The strain was transformed into competent cells of ISO-3 containing the pREDcas9 plasmid, and positive transformants were identified using primers U-mbhA-S / D-mbhA-A. The plasmid was lost in the same manner as step (3) of Example 2 to obtain strain ISO-4.

[0125] Example 7: Construction of L-isoleucine engineering strain ISO-5

[0126] (1) Overlapping fragment U ycgH -P trc -bcd-T trc -D ycgH Construction

[0127] Using the E. coli W3110 genome as a template, primers U-ycgH-S / U-ycgH-A and D-ycgH-S / D-ycgH-A were used to amplify the upstream and downstream homology arms of ycgH, respectively. Using the B. subtilis 168 genome as a template, primers bcd-A / bcd-S were used to amplify the P trc Promoter, T trc terminator and fragment P of bcd gene trc -bcd-T trc After the PCR product was recovered, the primers U-ycgH-S / D-ycgH-A were used to obtain the ycgH upstream and downstream homology arms, P trc -bcd-T trc Fusion fragment U ycgH -P trc -bcd-T trc -D ycgH .

[0128] (2) Construction of pGRB-ycgH plasmid

[0129] According to the ycgH sequence, the gRNA 20bp forward and reverse sequences pGRB-ycgH-S and pGRB-ycgH-A were designed and synthesized, and the recombinant plasmid pGRB-ycgH was constructed using the same method as step (2) of Example 2.

[0130] (3) Construction of L-isoleucine engineered strain ISO-5

[0131] The recombinant plasmid pGRB-ycgH and fusion fragment U ycgH -P trc -bcd-T trc -D ycgH The strain was transformed into competent cells of ISO-4 containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-ycgH-S / D-ycgH-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-5.

[0132] Example 8: Construction of L-isoleucine engineering strain ISO-6

[0133] (1) Overlapping fragment U ilvE -D ilvE Construction

[0134] Using the genome of E. coli W3110 as a template, the upstream and downstream homology arms of ilvE were amplified using primers U-ilvE-S / U-ilvE-A and D-ilvE-S / D-ilvE-A, respectively. Then, overlapping PCR was used to obtain a fusion fragment U containing the upstream and downstream homology arms of ilvE. ilvE -D ilvE .

[0135] (2) Construction of pGRB-ilvE plasmid

[0136] According to the ilvE sequence, the gRNA 20 bp forward and reverse sequences pGRB-ilvE-S and pGRB-ilvE-A were designed and synthesized. The recombinant plasmid pGRB-ilvE was constructed in the same manner as in step (2) of Example 2.

[0137] (3) Construction of L-isoleucine engineered strain ISO-6

[0138] The recombinant plasmid pGRB-ilvE and fusion fragment U ilvE -D ilvE The strain was transformed into ISO-5 competent cells containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-ilvE-S / D-ilvE-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-6.

[0139] Example 9: Construction of L-isoleucine engineering strain ISO-7

[0140] (1) Overlapping fragment U gapC -P trc -pntAB-T trc -D gapC Construction

[0141] Using the E. coli W3110 genome as a template, primers U-gapC-S / U-gapC-A, D-gapC-S / D-gapC-A, and pntAB-S / pntAB-A were used to amplify the upstream and downstream homology arms of gapC, as well as the region containing P trc Promoter, T trc terminator and fragment P of pntAB gene trc -pntAB-T trc After the PCR products were recovered, primers U-gapC-S / D-gapC-A were used to obtain the gapC upstream and downstream homology arms, P trc -pntAB-T trc Fusion fragment U gapC -P trc -pntAB-T trc -D gapC .

[0142] (2) Construction of pGRB-gapC plasmid

[0143] According to the gapC sequence, the gRNA 20bp forward and reverse sequences pGRB-gapC-S and pGRB-gapC-A were designed and synthesized, and the recombinant plasmid pGRB-gapC was constructed using the same method as step (2) of Example 2.

[0144] (3) Construction of L-isoleucine engineered strain ISO-7

[0145] The recombinant plasmid pGRB-gapC and fusion fragment U gapC -P trc -pntAB-T trc -D gapC The strain was transformed into competent cells of ISO-6 containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-gapC-S / D-gapC-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-7.

[0146] Example 10: Construction of L-isoleucine engineering strain ISO-8

[0147] (1) Construction of L-isoleucine engineered strain ISO-7ΔaceA

[0148] ① Overlapping fragment U aceA -D aceA Construction

[0149] Using the genome of E. coli W3110 as a template, the upstream and downstream homology arms of aceA were amplified using primers U-aceA-S / U-aceA-A and D-aceA-S / D-aceA-A, respectively. Then, overlapping PCR was used to obtain a fusion fragment U containing the upstream and downstream homology arms of aceA. aceA -D aceA .

[0150] ②Construction of pGRB-aceA plasmid

[0151] According to the aceA sequence, the gRNA 20 bp forward and reverse sequences pGRB-aceA-S and pGRB-aceA-A were designed and synthesized. The recombinant plasmid pGRB-aceA was constructed in the same manner as in step (2) of Example 2.

[0152] ③Construction of L-isoleucine engineering strain ISO-7ΔaceA

[0153] The recombinant plasmid pGRB-aceA and fusion fragment U aceA -D aceA The strain was transformed into ISO-7 competent cells containing pREDcas9 plasmid, and positive transformants were identified using primers U-aceA-S / D-aceA-A. The plasmid was lost in the same manner as step (3) of Example 2 to obtain strain ISO-7ΔaceA.

[0154] (2) Construction of L-isoleucine engineered strain ISO-7ΔaceAΔsucCD

[0155] ① Overlapping fragment U sucCD -D sucCD Construction

[0156] Using the genome of E. coli W3110 as a template, the upstream and downstream homology arms of sucCD were amplified using primers U-sucCD-S / U-sucCD-A and D-sucCD-S / D-sucCD-A, respectively. Then, overlapping PCR was used to obtain a fusion fragment U containing the upstream and downstream homology arms of sucCD. sucCD -D sucCD .

[0157] ②Construction of pGRB-sucCD plasmid

[0158] According to the sucCD sequence, the gRNA 20 bp forward and reverse sequences pGRB-sucCD-S and pGRB-sucCD-A were designed and synthesized. The recombinant plasmid pGRB-sucCD was constructed in the same manner as in step (2) of Example 2.

[0159] ③Construction of L-isoleucine engineering strain ISO-7ΔaceAΔsucCD

[0160] The recombinant plasmid pGRB-sucCD and fusion fragment U sucCD -D sucCD Transformed into ISO-7ΔaceA competent cells containing pREDcas9 plasmid, positive transformants were identified using primers U-sucCD-S / D-sucCD-A, and plasmid was lost in the same manner as step (3) of Example 2 to obtain strain ISO-7ΔaceAΔsucCD.

[0161] (3) L-isoleucine engineering strain ISO-7ΔaceAΔsucCDcysE::cysE M Construction

[0162] ① Overlapping fragment U cysE -D cysE and U cysE -cysE M -D cysE Construction

[0163] Using the E. coli W3110 genome as a template, the upstream and downstream homology arms of cysE were amplified using primers U-cysE-S1 / U-cysE-A1 and D-cysE-S1 / D-cysE-A1, respectively. Then, overlapping PCR was used to obtain a fusion fragment U containing the upstream and downstream homology arms of cysE. cysE -D cysE Using the genome of E. coli W3110 as a template, the upstream homology arm, downstream homology arm and cysE were amplified using primers U-cysE-S2 / U-cysE-A2, D-cysE-S2 / D-cysE-A2 and cysE-S / cysE-A, respectively. M Gene fragment (cysE M The gene fragment was mutated from the start codon ATG to GTG relative to cysE). After the PCR product was recovered, the primers U-cysE-S2 / D-cysE-A2 were used to obtain the upstream and downstream homologous arms of cysE, cysE M Fusion fragment U cysE -cysE M -D cysE .

[0164] ② Construction of pGRB-cysE-1 and pGRB-cysE-2 plasmids

[0165] According to the cysE sequence, the gRNA 20bp forward and reverse sequences pGRB-cysE-S1 and pGRB-cysE-A1 were designed and synthesized. The recombinant plasmid pGRB-cysE-1 was constructed in the same manner as in step (2) of Example 2. Similarly, the gRNA 20bp forward and reverse sequences pGRB-cysE-S2 and pGRB-cysE-A2 were designed and synthesized according to the insertion sequence. The recombinant plasmid pGRB-cysE-2 was constructed in the same manner as in step (2) of Example 2.

[0166] ③L-isoleucine engineering strain ISO-7ΔaceAΔsucCDcysE::cysE M Construction

[0167] The recombinant plasmid pGRB-cysE-1 and fusion fragment U cysE -D cysE Transformed into ISO-7ΔaceAΔsucCD competent cells containing pREDcas9 plasmid, positive transformants were identified using primers U-cysE-S1 / D-cysE-A1. Plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-7ΔaceAΔsucCDΔcysE. The recombinant plasmid pGRB-cysE-2 and fusion fragment U cysE -cysE M -D cysE Transform into ISO-7ΔaceAΔsucCDΔcysE competent cells containing pREDcas9 plasmid, and identify positive transformants using primers U-cysE-S2 / D-cysE-A2. Lose the plasmid in the same manner as step (3) of Example 2 to obtain strain ISO-7ΔaceAΔsucCDcysE::cysE M .

[0168] (4) Construction of L-isoleucine engineered strain ISO-8

[0169] ①Plasmid pUC19-metA-metB M Construction

[0170] The metA gene fragment was amplified using the E. coli W3110 genome as a template using primers metA-S / metA-A. The metB gene shown in SEQ ID NO.4 was synthesized using the gene M The gene fragment was used as a template and primers metB-S / metB-A were used to amplify the metB M After the PCR product was recovered, primers metA-S and metB-A were used to obtain the metA, metB MThe fusion fragment metA-metB M Linear pUC19 and fusion fragment metA-metB M The PCR product was recovered and connected using the recombination kit ClonExpress II One Step Cloning Kit, and then transformed into E. coli DH5α competent cells. The recombinant plasmid pUC19-metA-metB was obtained after screening in LB solid medium containing 100 μg / mL ampicillin and identification by colony PCR using primers metA-S / metB-A. M .

[0171] ②Construction of L-isoleucine engineering strain ISO-8

[0172] The recombinant plasmid pUC19-metA-metB M Transformation to ISO-7ΔaceAΔsucCDcysE::cysE M After the competent cells were revived, they were spread on LB solid medium containing 100 μg / mL ampicillin and cultured overnight at 37°C. The next day, colony PCR was performed using primers metA-S / metB-A to screen positive transformants and obtain strain ISO-8.

[0173] Example 11: Construction of L-isoleucine engineering strain ISO-9

[0174] (1) Overlapping fragment U rph -P trc -ygaZH-T trc -D rph Construction

[0175] Using the E. coli W3110 genome as a template, primers U-rph-S / U-rph-A, D-rph-S / D-rph-A, and ygaZH-S / ygaZH-A were used to amplify the upstream and downstream homology arms of rph, as well as the P trc Promoter, T trc The terminator and the fragment of ygaZH gene P trc -ygaZH-T trc After the PCR products were recovered, primers U-rph-S / D-rph-A were used to obtain overlapping PCR containing the upstream and downstream homology arms of rph, P trc -ygaZH-T trc Fusion fragment U rph -P trc -ygaZH-T trc -D rph (2) Construction of pGRB-rph plasmid

[0176] According to the rph sequence, the gRNA 20bp forward and reverse sequences pGRB-rph-S and pGRB-rph-A were designed and synthesized, and the recombinant plasmid pGRB-rph was constructed using the same method as step (2) of Example 2.

[0177] (3) Construction of L-isoleucine engineered strain ISO-9

[0178] The recombinant plasmid pGRB-rph and fusion fragment U rph -P trc -ygaZH-T trc -D rph The strain was transformed into competent cells of ISO-8 containing the pREDcas9 plasmid, and positive transformants were identified using primers U-rph-S / D-rph-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-9.

[0179] Example 12: Construction of L-isoleucine engineering strain ISO-10

[0180] (1) Overlapping fragment U rph -P trc -brnFE-T trc -D rph Construction

[0181] Using the E. coli W3110 genome as a template, the upstream and downstream homology arms of rph were amplified using primers U-rph-S / U-rph-A and D-rph-S / D-rph-A in step (1) of Example 11. Using the C. glutamicum ATCC13032 genome as a template, the primers brnFE-A / brnFE-S were used to amplify the P trc Promoter, T trc The terminator and the fragment P of the brnFE gene trc -brnFE-T trc After the PCR products were recovered, primers U-rph-S / D-rph-A were used to obtain overlapping PCR containing the upstream and downstream homology arms of rph, P trc -brnFE-T trc Fusion fragment U rph -P trc -brnFE-T trc -D rph .

[0182] (2) Construction of L-isoleucine engineered strain ISO-10

[0183] The recombinant plasmid pGRB-rph from step (2) of Example 11 and the fusion fragment U constructed in this example were rph -P trc -brnFE-T trc -D rph The strain was transformed into competent cells of ISO-8 containing the pREDcas9 plasmid, and positive transformants were identified using primers U-rph-S / D-rph-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-10.

[0184] Example 13: Construction of L-isoleucine engineering strain ISO-11

[0185] (1) Overlapping fragment U brnQ -D brnQ Construction

[0186] Using the E. coli W3110 genome as a template, primers U-brnQ-S / U-brnQ-A and D-brnQ-S / D-brnQ-A were used to amplify the upstream and downstream homology arms of brnQ. After the PCR product was recovered, the fusion fragment U containing the upstream and downstream homology arms of brnQ was obtained by overlapping PCR using primers U-brnQ-S / D-brnQ-A. brnQ -D brnQ .

[0187] (2) Construction of pGRB-brnQ plasmid

[0188] According to the brnQ sequence, the gRNA 20 bp forward and reverse sequences pGRB-brnQ-S and pGRB-brnQ-A were designed and synthesized. The recombinant plasmid pGRB-brnQ was constructed in the same manner as in step (2) of Example 2.

[0189] (3) Construction of L-isoleucine engineered strain ISO-11

[0190] The recombinant plasmid pGRB-brnQ and fusion fragment U brnQ -D brnQ The strain was transformed into ISO-10 competent cells containing the pREDcas9 plasmid, and the positive transformants were identified using primers U-brnQ-S / D-brnQ-A. The plasmid was lost in the same manner as in step (3) of Example 2 to obtain strain ISO-11.

[0191] Example 14: Shake flask fermentation of L-isoleucine engineered bacteria

[0192] (1) Seed culture

[0193] L-isoleucine genetically engineered bacteria ISO-1, ISO-2, ISO-3, ISO-4, ISO-5, ISO-6, ISO-7, ISO-8, ISO-9, ISO-10 and ISO-11 were inoculated onto LB solid medium slants, with E. coli W3110ΔlacI as a control, and cultured at 37°C for 12 hours. Then, they were inoculated into 30 mL seed culture medium and cultured at 37°C with shaking at 220 rpm for 6-8 hours.

[0194] (2) Fermentation culture

[0195] Inoculate the fermentation medium with 1% inoculum and culture at 35°C with shaking at 220 rpm for 20 hours. During the fermentation process, add 80% glucose 2-3 times to maintain the residual sugar concentration at 0.1-0.5% (W / V), 1 mL each time, and adjust the pH to about 7.0-7.5 with ammonia water.

[0196] (3) Detection of L-isoleucine in fermentation broth

[0197] After 20 hours of fermentation, the fermentation broth was centrifuged at 8000×g for 10 minutes, the supernatant was taken and diluted 10 times with deionized water, and then the fermentation broth was derivatized with 0.8% (V / V) 2,4-dinitrofluorobenzene, and the L-isoleucine content was determined by high performance liquid chromatography. The L-isoleucine production of each strain is shown in Table 1.

[0198] Table 1 L-isoleucine genetic engineering bacteria shake flask fermentation results

[0199] strain L-isoleucine production (g / L) E.coli W3110ΔlacI 0 ISO-1 0.9 ISO-2 4.6 ISO-3 6.7 ISO-4 8.8 ISO-5 11.2 ISO-6 11.8 ISO-7 14.3 ISO-8 21.7 ISO-9 24.3 ISO-10 26.9 ISO-11 30.1

[0200] The L-isoleucine production of the engineered strain ISO-11 reached 30.1 g / L after 20 h of fermentation, and the control strain E. coli W3110ΔlacI did not synthesize L-isoleucine (as shown in Table 1).

[0201] (4) Culture medium

[0202] Seed culture medium: 20 g / L glucose, 10 g / L yeast extract, 6 g / L peptone, 1.2 g / L KH2PO4, 0.5 g / LMgSO4·7H2O, 10 mg / L FeSO4·7H2O, 10 mg / L MnSO4·7H2O, 5 g / L L-threonine, 8 mg / L phenol red, the rest is water, pH 7.0-7.5, 115°C, high-pressure steam sterilization for 15 min.

[0203] Fermentation medium: 20 g / L glucose, 3 g / L yeast extract, 4 g / L peptone, 3 g / L KH2PO4, 1.8 g / LMgSO4·7H2O, 10 mg / L FeSO4·7H2O, 10 mg / L MnSO4·7H2O, 15 g / L L-threonine, 8 mg / L phenol red, the rest is water, pH 7.0-7.5, 115°C, high-pressure steam sterilization for 15 min.

[0204] Example 15: 5L fermentation tank fermentation of L-isoleucine engineering bacteria

[0205] (1) Seed culture

[0206] Use an inoculation loop to inoculate 3-5 strains of L-isoleucine engineering bacteria ISO-11 activated by fresh LB slant medium into a 5L fermenter filled with 2.5L seed medium, add 25% ammonia water to adjust the pH of the fermentation liquid to 7.0-7.5, and ventilate at 2-4m 3 / h, stirring speed 200-800rpm, culture at 37℃ for 6-8h.

[0207] (2) Fermentation culture

[0208] The seed culture of step (1) was inoculated with 10% of the inoculum into a 5L fermentation tank filled with 3L of fermentation medium for fermentation at a temperature of 35°C and a ventilation volume of 2-4m 3 / h, stirring speed 300-900rpm, tank pressure 0.06-0.10MPa, dissolved oxygen maintained at 30-40%, 80% glucose solution was fed, residual sugar concentration was maintained at 0.1-0.5% (W / V), 25% ammonia water was fed to adjust the pH of the fermentation liquid to 7.0-7.5.

[0209] (3) Detection of L-isoleucine in fermentation broth

[0210] The fermentation broth was centrifuged at 8000×g for 10 min, the supernatant was taken and diluted 10 times with deionized water, and then the fermentation broth was derivatized with 0.8% (V / V) 2,4-dinitrofluorobenzene, and the L-isoleucine content was determined by high performance liquid chromatography. After 48h of fermentation, the L-isoleucine production of L-isoleucine engineered bacteria ISO-11 reached 50.5g / L, the conversion rate was 29.6%, and the production intensity reached 1.05g / L / h.

[0211] (4) Culture medium

[0212] Same as step (4) of Example 14.

[0213] Example 16: Fermentation of L-isoleucine engineered bacteria ISO-11 in a 5L fermenter

[0214] (1) Seed culture

[0215] Same as step (1) of Example 15.

[0216] (2) Fermentation culture

[0217] The seed culture of step (1) was inoculated with 5% of the inoculum into a 5L fermentation tank filled with 3L of fermentation medium for fermentation at a temperature of 32°C and a ventilation volume of 2-3m 3 / h, stirring speed 200-900rpm, tank pressure 0.05-0.10MPa, dissolved oxygen maintained at 25-40%, 80% glucose solution added, residual sugar concentration maintained at 0.1-0.5% (W / V), 25% ammonia water added to adjust the pH of the fermentation liquid to 7.0-7.5. Fermentation for 40h.

[0218] (3) Detection of L-isoleucine in fermentation broth

[0219] Same as step (3) of Example 15. After 40 hours of fermentation, the L-isoleucine production of L-isoleucine engineered bacteria ISO-11 reached 45.3 g / L, the conversion rate was 26.3%, and the production intensity reached 1.13 g / L / h.

[0220] (4) Culture medium

[0221] Same as step (4) of Example 14.

[0222] Example 17: Fermentation of L-isoleucine engineered bacteria ISO-11 in a 5L fermenter

[0223] (1) Seed culture

[0224] Same as step (1) of Example 15.

[0225] (2) Fermentation culture

[0226] The seed culture of step (1) was inoculated with 8% inoculum into a 5L fermentation tank filled with 3L fermentation medium for fermentation culture. During the 0-12h of fermentation, the fermentation temperature was set at 37°C and the ventilation volume was 2-4m 3 / h, stirring speed 400-900rpm, tank pressure 0.1-0.15MPa, dissolved oxygen maintained at 40-50%. Fermentation 12-40h, set fermentation temperature 35℃, ventilation volume 3-5m 3 / h, stirring speed 500-900rpm, tank pressure 0.05-0.10MPa, dissolved oxygen maintained at 30-40%, 80% glucose solution added, residual sugar concentration maintained at 0.1-0.5% (W / V), 25% ammonia water added to adjust the pH of the fermentation liquid to 7.0-7.5. Fermentation for 40h.

[0227] (3) Detection of L-isoleucine in fermentation broth

[0228] Same as step (3) of Example 15. After 40 hours of fermentation, the engineered strain ISO-11 had an L-isoleucine yield of 61.9 g / L, a conversion rate of 31.9%, and a production intensity of 1.54 g / L / h. The above L-isoleucine yield, conversion rate, and production intensity are the highest indicators reported so far, and the fermentation cycle is the shortest reported so far.

[0229] (4) Culture medium

[0230] Same as step (4) of Example 14.

[0231] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the patent. It should be pointed out that, for ordinary technicians in this field, the above-mentioned implementation methods can also be modified, combined and improved without departing from the concept of this patent, which all belong to the protection scope of this patent. Therefore, the protection scope of this patent shall be based on the claims.

Claims

1. A threonine dehydratase mutant, characterized in that The amino acid sequence is shown in SEQ ID NO.

1.

2. A gene encoding the threonine dehydratase mutant according to claim 1.

3. The coding gene according to claim 2, characterized in that The nucleotide sequence is shown in the sequence listing SEQ ID NO.

2.

4. Use of the threonine dehydratase mutant according to claim 1.

5. The use according to claim 4, characterized in that The invention relates to an application in relieving the feedback inhibition of L-isoleucine or in producing L-isoleucine.

6. A method for producing L-isoleucine, characterized in that: The method uses Escherichia coli as a starting strain, knocks out the lactose operon repressor protein encoding gene lacI on the genome, and overexpresses the threonine dehydratase encoding gene ilvA described in claim 2 on the genome. M , overexpression of the ilvBN gene encoding the acetohydroxyacid synthase that relieves feedback inhibition in the genome M , overexpressing aspartate kinase / homoserine dehydrogenase encoding gene thrA, homoserine kinase encoding gene thrB and threonine synthetase encoding gene thrC in the genome, overexpressing aspartate aminotransferase encoding gene aspA in the genome, overexpressing Bacillus subtilis leucine dehydrogenase encoding gene bcd in the genome, knocking out branched chain amino acid aminotransferase encoding gene ilvE, overexpressing pyridine nucleotide transhydrogenase encoding gene pntAB in the genome, knocking out isocitrate lyase encoding gene aceA, knocking out succinyl-CoA synthetase encoding gene sucCD, replacing the start codon ATG of serine acetyltransferase encoding gene cysE with GTG in the genome, overexpressing homoserine-O-acyltransferase encoding gene metA and cystathionine-γ-synthase mutant encoding gene metB M This is achieved by overexpressing the L-isoleucine export protein encoding gene ygaZH or brnFE in the genome and knocking out the L-isoleucine import protein encoding gene brnQ.

7. The method for producing L-isoleucine according to claim 6, wherein The starting strain of Escherichia coli is Escherichia coli W3110; Plasmids for overexpression of metA, a homoserine-O-acyltransferase gene, and metB, a cystathionine-γ-synthase mutant gene M .

8. The method for producing L-isoleucine according to claim 6, wherein The lactose operon repressor protein encoding gene lacI is from Escherichia coli W3110, Protein ID in NCBI: BAE76127.1; The threonine dehydratase encoding gene ilvA M Derived from Corynebacterium glutamicum ILE693, the nucleotide sequence is shown in SEQ ID NO.2; The acetohydroxyacid synthase encoding gene ilvBN M Derived from Corynebacterium glutamicum ILE693, the nucleotide sequence is shown in SEQ ID NO.3; The aspartate kinase / homoserine dehydrogenase encoding gene thrA, homoserine kinase encoding gene thrB and threonine synthetase encoding gene thrC are from Escherichia coli W3110, with Protein IDs in NCBI: BAB96579.2, BAB96580.2 and BAB96581.1; The aspartate aminotransferase encoding gene aspA is from Escherichia coli W3110, Protein ID in NCBI: BAE78141.1; The leucine dehydrogenase encoding gene bcd is from Bacillus subtilis 168, Protein ID in NCBI: NP_390288.1; The branched chain amino acid aminotransferase encoding gene ilvE is from Escherichia coli W3110, NCBI Protein ID: BAE77527.1; The pyridine nucleotide transhydrogenase encoding gene pntAB is from Escherichia coli W3110, Protein ID in NCBI: BAA15342.1-BAA15336.1; The isocitrate lyase encoding gene aceA is from Escherichia coli W3110, and its Protein ID in NCBI is: BAE78017.1; The succinyl-CoA synthetase encoding gene sucCD is from Escherichia coli W3110, Protein ID in NCBI: BAA35394.1-BAA35395.1; The serine acetyltransferase encoding gene cysE is from Escherichia coli W3110, Protein ID in NCBI: BAE77685.1; The homoserine-O-acyltransferase encoding gene metA is from Escherichia coli W3110, Protein ID in NCBI: BAE78015.1; The cystathionine-γ-synthase mutant encoding gene metB M , the nucleotide sequence is shown in SEQ ID NO.4; The L-isoleucine export protein encoding gene ygaZH is from Escherichia coli W3110, Protein ID in NCBI: BAE76784.1-BAA16545.1; The L-isoleucine export protein encoding gene brnFE is from Corynebacterium glutamicum 13032, Protein ID in NCBI: CAF18829.1-CAF18830.1; The L-isoleucine import protein encoding gene brnQ is from Escherichia coli W3110, Protein ID in NCBI: BAE76181.

1.

9. A strain for producing L-isoleucine constructed by the method of claim 7 or 8.

10. Use of the strain according to claim 9 in producing L-isoleucine.

Citation Information

Cited By

  • Cystathionine-gamma-synthase mutant and application thereof

    CN117165549A

  • A cystathionine-gamma-synthase mutant and use thereof

    CN117165549B

  • Genetically engineered bacterium for producing L-isoleucine as well as construction method and application of genetically engineered bacterium

    CN121022705A

  • Leucine dehydrogenase mutant, valine production strain comprising leucine dehydrogenase mutant and application of valine production strain

    CN122128265A

  • Use of ncgl0762 protein and mutant thereof in production of l-isoleucine

    WO2026145083A1